---
title: "10-Deacetylbaccatin III Market, Global Outlook and Forecast 2025-2032"
datePublished: Mon Nov 24 2025 00:01:16 GMT+0000 (Coordinated Universal Time)
cuid: cmicdt1mo000202l7drqehmoo
slug: 10-deacetylbaccatin-iii-market-global-outlook-and-forecast-2025-2032

---

# 10-Deacetylbaccatin III Market, Global Outlook and Forecast 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global 10-Deacetylbaccatin III market was valued at USD 64.7 million in 2024 and is projected to reach USD 85.9 million by 2032, growing at a CAGR of 4.2% during the forecast period. This growth is primarily driven by increasing demand for taxane-based cancer therapeutics, particularly docetaxel and paclitaxel, where 10-Deacetylbaccatin III serves as a key intermediate.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/297794/global-deacetylbaccatin-iii-forecast-market">
            https://www.24chemicalresearch.com/download-sample/297794/global-deacetylbaccatin-iii-forecast-market</a></b></div><br><p>
</p><p>10-Deacetylbaccatin III (10-DAB III) is a naturally occurring taxane compound extracted from the needles and branches of the European yew tree (Taxus baccata). This bioactive molecule is recognized for its significant role as a precursor in the semi-synthesis of several important anti-cancer drugs, including docetaxel (Taxotere) and paclitaxel (Taxol). Furthermore, research has demonstrated its direct therapeutic potential, with studies showing an IC50 value of 70 nM against Leishmania donovani intracellular amastigotes, indicating promising applications beyond oncology.</p><p>
</p><p>The market growth is supported by the expanding pharmaceutical industry in emerging economies and increasing cancer prevalence worldwide. China currently dominates the market with over 35% share, while North America and Europe collectively account for more than 50% of global demand. The &gt;98.0% purity segment represents the largest product category with 85% market share, reflecting the stringent quality requirements for pharmaceutical applications. Key players like SM Herbals, Alchem International, and Indena collectively hold over half of the market, leveraging their expertise in botanical extraction and chemical synthesis.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Growing Demand for Taxane-Based Anticancer Drugs to Fuel Market Expansion</strong></p><p>
</p><p>The global 10-Deacetylbaccatin III market is witnessing robust growth due to its critical role as a precursor in manufacturing taxane-based anticancer drugs like paclitaxel and docetaxel. With cancer incidence rates rising globally, particularly breast, lung, and ovarian cancers, the demand for these life-saving drugs has increased significantly. Paclitaxel alone accounts for nearly 40% of all chemotherapy drugs used in cancer treatment regimens today. The compound's unique mechanism of action that stabilizes microtubules makes it indispensable in oncology protocols, driving consistent demand for high-purity 10-Deacetylbaccatin III from pharmaceutical manufacturers.</p><p>
</p><p style="text-align:center"><strong>Advancements in Extraction Technologies Enhancing Yield and Purity</strong></p><p>
</p><p>Technological improvements in extraction and purification processes are significantly boosting market growth. Modern supercritical fluid extraction techniques have increased yields from yew biomass by approximately 25-30% compared to traditional solvent-based methods. Additionally, innovations in chromatographic separation allow producers to achieve purity levels exceeding 98.5%, meeting stringent pharmaceutical requirements. These advancements not only improve operational efficiency but also help offset raw material constraints by maximizing output from limited yew resources.</p><p>
</p><p style="text-align:center"><strong>Expanding Application in Novel Drug Development Creating New Growth Avenues</strong></p><p>
</p><p>Recent research has uncovered promising applications of 10-Deacetylbaccatin III derivatives in treating other conditions beyond cancer, including antimicrobial and anti-inflammatory therapies. The compound has shown significant activity against leishmaniasis with demonstrated IC50 values below 100 nM in clinical studies. Pharmaceutical companies are increasingly investing in exploring these novel therapeutic applications, which is expected to diversify demand streams and reduce reliance on traditional cancer drug markets alone.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Limited Availability of Raw Material Creating Supply Chain Bottlenecks</strong></p><p>
</p><p>The market faces significant constraints due to the limited natural availability of Taxus species, particularly the European yew (Taxus baccata), which remains the primary source of 10-Deacetylbaccatin III. These slow-growing trees require 7-10 years to reach maturity before sustainable harvesting can begin. With increasing environmental regulations protecting yew populations in many regions, manufacturers face growing challenges in securing consistent raw material supplies at stable prices.</p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Compliance Increasing Production Costs</strong></p><p>
</p><p>The pharmaceutical-grade production of 10-Deacetylbaccatin III is subject to rigorous quality standards, including current Good Manufacturing Practices (cGMP) and various pharmacopeia specifications. Compliance with these regulations requires substantial capital investment in specialized equipment and quality control systems, with validation costs sometimes representing 15-20% of total production expenses. These requirements create significant barriers to entry for new market players and limit production scalability for existing manufacturers.</p><p>
</p><p style="text-align:center"><strong>Emerging Alternative Production Methods Threatening Traditional Supply Chains</strong></p><p>
</p><p>The development of alternative production methods, particularly plant cell culture technology and semi-synthetic pathways, presents challenges to traditional extraction-based manufacturers. Some pharmaceutical companies have successfully developed fermentation-based production systems that can achieve 10-Deacetylbaccatin III yields exceeding 1g/L, potentially reducing dependence on yew tree sources. While still in relatively early stages, these technologies could disrupt existing market dynamics if successfully commercialized at scale.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Strategic Partnerships in Emerging Markets Offering Growth Potential</strong></p><p>
</p><p>Asia-Pacific presents significant opportunities for market expansion, particularly through partnerships with local pharmaceutical manufacturers in China and India. These countries are making substantial investments in oncology drug production capacity and have become major exporters of generic cancer medications. With the region accounting for over 35% of global 10-Deacetylbaccatin III consumption, strategic collaborations can provide established producers with access to growing markets while benefiting from local manufacturing advantages.</p><p>
</p><p style="text-align:center"><strong>Sustainable Cultivation Initiatives Addressing Raw Material Challenges</strong></p><p>
</p><p>Investment in sustainable yew cultivation programs offers promising solutions to raw material shortages. Several European countries have implemented successful Taxus plantation projects that have increased biomass availability by approximately 18-22% annually. Similar initiatives in North America and Asia, combined with advancements in agricultural biotechnology, could significantly improve supply security while meeting environmental sustainability criteria demanded by regulatory agencies and consumers alike.</p><p>
</p><p style="text-align:center"><strong>Development of High-Purity Formulations for Precision Medicine</strong></p><p>
</p><p>The growing emphasis on precision oncology creates opportunities for manufacturers to develop ultra-high purity (&gt;99.5%) 10-Deacetylbaccatin III formulations. These specialized grades command premium pricing (typically 25-30% higher than standard pharmaceutical grade) and are increasingly required for next-generation targeted therapies. Companies investing in advanced purification technologies are well-positioned to capitalize on this emerging high-value market segment.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Price Volatility in Raw Materials Impacting Profit Margins</strong></p><p>
</p><p>The market faces significant challenges from fluctuating prices of yew biomass, which can vary by as much as 40% between harvesting seasons. This volatility is compounded by changing environmental regulations that affect harvesting quotas in key sourcing regions. Manufacturers often struggle to pass these cost variations downstream due to fixed-price contracts with pharmaceutical customers, resulting in margin compression that can reach 10-15% during periods of supply shortages.</p><p>
</p><p style="text-align:center"><strong>Technical Complexities in Large-Scale Production</strong></p><p>
</p><p>Scaling up 10-Deacetylbaccatin III production while maintaining strict quality standards presents significant technical challenges. The compound's complex molecular structure makes it particularly sensitive to process conditions, with yield losses of 5-7% commonly occurring during scale-up transitions. Manufacturers must invest heavily in process optimization and quality control systems to ensure batch-to-batch consistency, with validation processes often requiring 12-18 months for new production lines.</p><p>
</p><p style="text-align:center"><strong>Competition from Alternative Therapies Impacting Long-Term Demand</strong></p><p>
</p><p>While taxane-based drugs remain essential in cancer treatment, emerging alternative therapies such as immunotherapy and targeted molecular drugs are gaining prominence in oncology protocols. These newer treatment modalities now account for approximately 35% of first-line cancer therapies in developed markets, creating long-term demand challenges for traditional chemotherapy ingredients like 10-Deacetylbaccatin III. Manufacturers must adapt by developing innovative derivatives or exploring alternative therapeutic applications to maintain market relevance.</p><p>
</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Above 98.0% Purity Segment Dominates Due to High Pharmaceutical Demand for Anti-Cancer Drug Synthesis</strong></p><p>
</p><p>The 10-Deacetylbaccatin III market is segmented based on purity levels into:</p><p>
</p><p>Above 95%</p><p>Above 98.0%</p><p>
	</p><p>Subtypes: 98.5%, 99.0%, and higher grades</p><p>Others</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Production of Docetaxel Leads Market Share as Primary Therapeutic Application</strong></p><p>
</p><p>The market is segmented by key pharmaceutical applications into:</p><p>
</p><p>Production of Docetaxel</p><p>Production of Paclitaxel</p><p>Research applications</p><p>
	</p><p>Subtypes: Anti-leishmanial studies, other therapeutic research</p><p>Others</p><p>
<strong>By End-User Industry</strong></p><p>
</p><p><strong>Pharmaceutical Manufacturers Account for Major Consumption Volume</strong></p><p>
</p><p>The market is segmented by end-user industries into:</p><p>
</p><p>Pharmaceutical companies</p><p>Biotechnology firms</p><p>Academic research institutions</p><p>Contract research organizations</p><p>
<strong>By Production Method</strong></p><p>
</p><p><strong>Natural Extraction Remains Preferred Method due to Plant-Derived Source Requirements</strong></p><p>
</p><p>The market is segmented by production techniques into:</p><p>
</p><p>Natural extraction (Taxus baccata)</p><p>Semi-synthetic production</p><p>Alternative production methods</p><p>
</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Strategic Expansion and R&amp;D Investments Drive Market Competition</strong></p><p>
</p><p>The <strong>10-Deacetylbaccatin III market</strong> exhibits a semi-consolidated structure with dominant players holding significant market shares. <strong>SM Herbals</strong>, <strong>Alchem International</strong>, and <strong>Indena</strong> collectively command over 50% of global revenue as of 2024, leveraging their established supply chains and vertically integrated production processes. China remains the epicenter of manufacturing activity, where these companies benefit from proximity to yew tree cultivation regions and cost-effective extraction technologies.</p><p>
</p><p>While <strong>SM Herbals</strong> leads in production capacity with facilities across Jiangsu and Shandong provinces, <strong>Indena</strong> has strengthened its European market position through patented purification techniques that yield &gt;98% purity grades - now representing 85% of their product mix. Meanwhile, <strong>Alchem International</strong> reported a 12% year-over-year revenue increase in 2024, attributed to expanded API manufacturing partnerships with oncology drug developers.</p><p>
</p><p>Mid-tier participants like <strong>South Pharmaceutical</strong> and <strong>Hainan Yew Pharmaceutical</strong> are gaining traction through niche strategies. The former specializes in custom derivatives for research applications, while the latter capitalizes on China's domestic pharmaceutical demand, which consumes 35% of global 10-DAB III output.</p><p>
</p><p>The competitive landscape is further evolving through technological partnerships. <strong>Aphios Corporation</strong> recently licensed supercritical fluid extraction technology to enhance yields, while <strong>Sai Phytoceuticals</strong> acquired analytical testing capabilities to meet stringent FDA and EMA standards for taxane precursors.</p><p>
<strong>List of Key 10-Deacetylbaccatin III Producers</strong></p><p>
</p><p>SM Herbals (China)</p><p>Alchem International (India)</p><p>Indena S.p.A. (Italy)</p><p>South Pharmaceutical (China)</p><p>HAOXUAN Bio-Tech (China)</p><p>Yuannan Hande Biotechnology (China)</p><p>Sai Phytoceuticals (India)</p><p>Sarv Biolabs Pvt Ltd (India)</p><p>Aphios Corporation (U.S.)</p><p>Hainan Yew Pharmaceutical (China)</p><p>
</p><p>
<strong>10-DEACETYLBACCATIN III MARKET TRENDS</strong></p><p>
<strong>Increasing Demand for Anticancer Drugs Driving Market Growth</strong></p><p>
</p><p>The global 10-Deacetylbaccatin III market is experiencing significant growth due to its critical role as a precursor in synthesizing anticancer drugs like docetaxel and paclitaxel. With cancer prevalence rising at an annual rate of approximately 2-3%, pharmaceutical manufacturers are scaling up production of taxane-based therapies. <strong>The compound's ability to inhibit L. donovani at nanomolar concentrations (IC50 of 70 nM)</strong> has further expanded its therapeutic applications beyond oncology. Market projections indicate steady expansion, with China maintaining dominance as both a production hub and consumption center, accounting for over 35% of global demand. This growth is directly tied to increasing healthcare expenditure in emerging economies, where cancer treatment accessibility continues to improve.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Purity Standards and Grade Segmentation</strong></p><p>
</p><p>The market is seeing heightened demand for high-purity 10-Deacetylbaccatin III, particularly the &gt;98.0% grade which dominates with 85% market share. This preference stems from strict regulatory requirements in pharmaceutical manufacturing where impurity profiles directly affect drug efficacy and safety approvals. While lower purity grades (&gt;95%) find application in research settings, commercial-scale drug production consistently requires the highest specifications. This trend aligns with broader industry movements toward standardized, GMP-compliant intermediates that reduce downstream processing challenges and improve batch consistency.</p><p>
<strong>Strategic Consolidation Among Key Producers</strong></p><p>
</p><p>Market leadership remains concentrated among three major players who collectively control over 50% of production capacity. This oligopolistic structure is driving vertical integration strategies, with manufacturers like SM Herbals and Alchem International expanding cultivation partnerships for Taxus baccata raw materials. Simultaneously, strategic acquisitions are occurring as smaller suppliers struggle with the capital-intensive nature of Good Manufacturing Practice (GMP) compliance. The European and North American markets demonstrate particular price sensitivity to these supply chain dynamics, given their reliance on imports from primary Asian producers.</p><p>
</p><p>
<strong>Regional Analysis: 10-Deacetylbaccatin III Market</strong></p><p>
</p><p><strong>North America</strong></p><p>
The North American market for 10-Deacetylbaccatin III is driven by robust pharmaceutical R&amp;D and well-established oncology treatment infrastructure. The U.S. holds the dominant position in the region due to high demand for docetaxel and paclitaxel production, with cancer treatment spending projected to exceed $200 billion annually. Strict FDA regulations ensure quality standards for precursor materials, creating a preference for high-purity (98%+) grades. While Canada contributes to regional demand, its market remains smaller due to centralized healthcare procurement systems. Recent partnerships between U.S. biotech firms and Asian raw material suppliers are optimizing supply chains to ensure consistent 10-DAB availability for critical drug manufacturing.</p><p>
</p><p><strong>Europe</strong></p><p>
Europe represents a mature yet stable market for 10-Deacetylbaccatin III, with Germany, France, and the UK leading consumption. The region benefits from advanced taxane drug manufacturing capabilities and strong environmental protections for yew tree cultivation. EU pharmacopeia standards mandate rigorous testing protocols for botanical derivatives like 10-DAB, favoring established suppliers with certified extraction facilities. Emerging sustainability initiatives are prompting manufacturers to explore alternative sourcing methods, including cell culture technologies. However, limited domestic yew tree resources create import dependence, particularly from China and India. The region's emphasis on biosimilars development presents long-term opportunities for 10-DAB applications beyond traditional oncology drugs.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
As the global production hub for 10-Deacetylbaccatin III, Asia-Pacific supplies over 60% of worldwide demand. China dominates both production and consumption, leveraging extensive yew tree plantations in Yunnan and Sichuan provinces. Local manufacturers benefit from vertically integrated supply chains connecting raw material suppliers with pharmaceutical exporters. India's growing generic drug industry fuels secondary demand, though quality inconsistencies in lower-grade 10-DAB remain a concern. Japan and South Korea maintain premium-priced segments for ultra-high purity formulations. Regional expansion is constrained by environmental policies limiting wild yew harvesting, prompting investment in semi-synthetic production methods. The API manufacturing boom across Southeast Asia is creating new application pathways for 10-DAB in next-generation taxanes.</p><p>
</p><p><strong>South America</strong></p><p>
The South American market shows nascent but promising growth potential, primarily centered in Brazil and Argentina. Limited local production capacity creates reliance on imports from China and Europe, particularly for pharmaceutical-grade material. Brazil's developing oncology healthcare infrastructure generates steady demand, though economic fluctuations periodically disrupt procurement cycles. Argentina's biotechnology sector has demonstrated capability in taxane research, but lacks scale for commercial 10-DAB production. Regulatory harmonization efforts across MERCOSUR countries could facilitate market expansion if combined with strategic partnerships with global suppliers. The region's biodiversity offers untapped potential for alternative plant-derived precursors, though extraction expertise remains underdeveloped compared to Asian counterparts.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
This region presents a developing market scenario with uneven growth patterns. Turkey and South Africa emerge as the most active markets, driven by improving cancer care infrastructure and government healthcare investments. GCC countries import high-value oncology drugs containing 10-DAB derivatives, but lack local pharmaceutical conversion capabilities. Africa faces supply chain challenges due to fragmented distribution networks and limited cold storage for sensitive APIs. Recent collaborations between Middle Eastern hospitals and European drug manufacturers may stimulate secondary demand. While not currently a production base, Morocco and Egypt show potential as future cultivation sites for Taxus species due to favorable climatic conditions and lower land costs compared to traditional growing regions.</p><p>

</p><p></p><p><strong>Key Report Takeaways</strong></p><p></p><p>
</p><p>
</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for 10-Deacetylbaccatin III, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed 10-Deacetylbaccatin III manufacturers, suppliers, distributors, and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global 10-Deacetylbaccatin III Market?</strong></p><p>
</p><p><strong>-&gt;</strong> The global 10-Deacetylbaccatin III market was valued at <strong>USD 64.7 million in 2024</strong> and is expected to reach <strong>USD 85.9 million by 2032</strong>, growing at a CAGR of 4.2% during the forecast period.</p><p>
<strong>Which key companies operate in Global 10-Deacetylbaccatin III Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>SM Herbals, Alchem International, Indena, South Pharmaceutical, HAOXUAN, Yuannan Hande, Sai Phytoceuticals, Sarv Biolabs Pvt, Aphios, and Hainan Yew Pharmaceutical</strong>, with the top three manufacturers holding over 50% market share.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>increasing demand for taxane-based cancer drugs, rising prevalence of cancer globally, and expansion of pharmaceutical manufacturing capabilities in emerging markets</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; China</strong> is the largest market with over 35% share, followed by <strong>North America and Europe</strong> which collectively account for more than 50% of global demand.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>development of sustainable extraction methods, research into new therapeutic applications beyond oncology, and increasing focus on high-purity (&gt;98%) 10-Deacetylbaccatin III production</strong>.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/297794/global-deacetylbaccatin-iii-forecast-market">
            https://www.24chemicalresearch.com/reports/297794/global-deacetylbaccatin-iii-forecast-market</a></b></div><br>
            <b>Table of Content:</b><p>1 Introduction to Research & Analysis Reports<br />
 1.1 10-Deacetylbaccatin III Market Definition<br />
 1.2 Market Segments<br />
 1.2.1 Segment by Type<br />
 1.2.2 Segment by Application<br />
 1.3 Global 10-Deacetylbaccatin III Market Overview<br />
 1.4 Features & Benefits of This Report<br />
 1.5 Methodology & Sources of Information<br />
 1.5.1 Research Methodology<br />
 1.5.2 Research Process<br />
 1.5.3 Base Year<br />
 1.5.4 Report Assumptions & Caveats<br />
2 Global 10-Deacetylbaccatin III Overall Market Size<br />
 2.1 Global 10-Deacetylbaccatin III Market Size: 2024 VS 2032<br />
 2.2 Global 10-Deacetylbaccatin III Market Size, Prospects & Forecasts: 2020-2032<br />
 2.3 Global 10-Deacetylbaccatin III Sales: 2020-2032<br />
3 Company Landscape<br />
 3.1 Top 10-Deacetylbaccatin III Players in Global Market<br />
 3.2 Top Global 10-Deacetylbaccatin III Companies Ranked by Revenue<br />
 3.3 Global 10-Deacetylbaccatin III Revenue by Companies<br />
 3.4 Global 10-Deacetylbaccatin III Sales by Companies<br />
 3.5 Global 10-Deacetylbaccatin III Price by Manufacturer (2020-2025)<br />
 3.6 Top 3 and Top 5 10-Deacetylbaccatin III Companies in Global Market, by Revenue in 2024<br />
 3.7 Global Manufacturers 10-Deacetylbaccatin III Product Type<br />
 3.8 Tier 1, Tier 2, and Tier 3 10-Deacetylbaccatin III Players in Global Market<br />
 3.8.1 List of Global Tier 1 10-Deacetylbaccatin III Companies<br />
 3.8.2 List of Global Tier 2 and Tier 3 10-Deacetylbaccatin III Companies<br />
4 Sights by Product<br />
 4.1 Overview<br />
 4.1.1 Segment by Type - Global 10-Deacetylbaccatin III Market Size Markets, 2024 & 2032<br />
 4.1.2 Above 95%<br />
 4.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/297794/global-deacetylbaccatin-iii-forecast-market">
            https://www.24chemicalresearch.com/reports/297794/global-deacetylbaccatin-iii-forecast-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>